DrugPatentWatch Database Preview
BRONCHITOL Drug Profile
» See Plans and Pricing
Which patents cover Bronchitol, and when can generic versions of Bronchitol launch?
Bronchitol is a drug marketed by Chiesi and is included in one NDA.
The generic ingredient in BRONCHITOL is mannitol. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the mannitol profile page.
Summary for BRONCHITOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 149 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,141 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in BRONCHITOL? | BRONCHITOL excipients list |
| DailyMed Link: | BRONCHITOL at DailyMed |
Recent Clinical Trials for BRONCHITOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Pittsburgh | N/A |
| Pharmaxis | Phase 3 |
| Pharmaxis | Phase 2 |
Pharmacology for BRONCHITOL
| Drug Class | Osmotic Diuretic |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for BRONCHITOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiesi | BRONCHITOL | mannitol | POWDER;INHALATION | 202049-001 | Oct 30, 2020 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Get Started for $10 | ||||
| Chiesi | BRONCHITOL | mannitol | POWDER;INHALATION | 202049-001 | Oct 30, 2020 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Get Started for $10 | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
